The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1270 articles
The rise in popularity of weight loss medications such as Ozempic and Mounjaro is significantly impacting both the food industry and the stock market. Eli Lilly, a pharmaceutical company, experienced a surge in valuation after reporting substantial sales increases. These drugs are changing eating patterns and redefining obesity treatment.
Blockbuster weight-loss shots are evolving, with new treatments in development that aim to improve upon current injections. Drugmakers are developing a new wave of GLP-1 treatments, with several promising candidates in the pipeline. These experimental treatments aim to address some of the biggest gripes about today's injections.
Berberine, a compound found in several plants, has gained attention for its potential health benefits, including weight loss and blood sugar regulation. Some compare it to Ozempic, but experts caution about its effectiveness and safety compared to prescription medications.
Semax, a synthetic heptapeptide, has demonstrated neuroregulatory, neuroprotective, and immunomodulating properties in various research models. This article examines its biochemical characteristics, possible effects on gene expression, interactions with neurotransmitter systems, vascular modulation, metal binding, and utility in ischemia-reperfusion injury studies.
New weight loss drugs, potentially available in oral form, are under development by Eli Lilly and Novo Nordisk. These medications aim to manage type-2 diabetes and facilitate weight loss, potentially offering a more accessible and convenient alternative to current injectables.
Following Novo Nordisk's price reduction for its Wegovy injection, generic drug manufacturers are reassessing their pricing strategies. The move comes amid increasing competition in the weight-loss drug market, with potential impacts on affordability and market share.
A new Optum Rx report identifies three drugs targeting chronic conditions that are under review by the FDA. The medications address significant cost drivers for payers, including weight management and chronic inflammatory conditions.
A prominent home services company in the UAE has begun delivering weight-loss medications, indicating the sustained popularity of GLP-1 drugs. This move raises discussions about accessibility and safety when obtaining prescription drugs online.
GLP-1 agonists, initially for blood sugar and weight loss, are now investigated for their impact on sexual function. Studies reveal diverse effects on libido, influenced by various factors. Some experience increased libido, while others report a decline.
